NCT Number: NCT00308347
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
Looking for future studies?
Notify MeKey information
Conditions
Age range
31 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diabetes diagnosed after the age of 30
- Insulin not required within 6 months of first being diagnosed with Non-insulin Dependent Diabetes Mellitus
- No history of diabetic ketoacidosis
- Patients may be currently treated with diet, oral hypoglycemics or insulin
- Patients must have proteinuria defined as: Urine protein >1+ on dipstick at the initial screening visit
- Patients with hypertension (high blood pressure) must have a sitting blood pressure >200/110 mm Hg at Visit 1
Exclusion criteria
- Patients with insulin-dependent diabetes mellitus (juvenile onset)
- Patients treated with an ACE inhibitor or angiotensin II antagonist (AIIA) for >5 years
- Patients treated with ACE inhibitor or AIIA therapy for 5 years or less may enter the study provided therapy is discontinued during the 6 week screening period prior to randomization
- History of myocardial infarction (MI) (heart attack) or coronary artery bypass graft (CABG) surgery within the past 1 month
- History of cerebral vascular accident (CVA) (stroke) or percutaneous transluminal coronary angioplasty (PTCA) within the past 6 months
- History of transient ischemic attacks (TIA) within the past year. Patients with unstable angina are excluded until stabilized
- Heart failure requiring ACE inhibitor therapy
- Steroids (oral or parenteral) or immunosuppressives are not permitted. Debilitating psychological illness
- Evidence of significant hepatic (liver) dysfunction: History of allergy to losartan
- Known positive test for HIV or patients known to be hepatitis B or C antigen carriers
- Pregnant or nursing women
- Females of childbearing age must either be surgically sterilized or, if sexually active, using an effective form of contraception and may enter only if an exclusionary pregnancy test is done within approximately 72 hours prior to randomization
- Pregnancy tests will be done every 3 months during the study and at the time of discontinuation
Treatment and study plan
Placebo / Duration of Treatment: mean 3.4 years
DrugPrimary outcomes
-
Combined endpoint of doubling of serum creatinine, ESRD or death.
Secondary outcomes
-
Secondary parameters: number of cardiovascular events and changes in proteinuria. Tertiary parameters: quality of life and healthcare resource utilization.
Sponsors and collaborators
Lead sponsor
Organon and Co
Industry
Registry information
Official study title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy
Important dates
- Study start
- 1996
- Primary completion
- 2001
- Study completion
- 2001
- First posted
- Mar 29, 2006
- Registry last updated
- Feb 15, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
NCT02818192
Diabetes Mellitus, Diabetes Mellitus, Type 2
Winnipeg, Manitoba, Canada
View Trial DetailsSacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
NCT06501651
Cardiovascular Diseases, Diabetes Mellitus
Chengdu, Sichuan, China
View Trial DetailsRenal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
NCT05530356
Adolescent Obesity, Body Weight
Aurora, Colorado, United States
View Trial DetailsEarly Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
NCT07465926
Body Weight, Cardiovascular Disease Risk Factor
View Trial Details